Fusion Pharmaceuticals (FUSN) Stock

HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement. The Arrangement marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

Fusion (FUSN) is anticipated to share updates on the progress of its main candidate, FPI-2265, for prostate cancer during the first-quarter earnings report.

Fusion Pharmaceuticals Inc. (FUSN) ended the latest trading session at $21.36, showing no change from the day before.

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.

HAMILTON, ON and BOSTON , March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. Presentation at AACR Annual Meeting 2024: Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) Session: Phase II Clinical Trials 1 Session Date and Time: Tuesday April 9, 2024, 9:00 a.m – 12:30 p.m.

Fusion Pharmaceuticals is an oncology company focused on precision medicine and radiopharmaceuticals. The company's clinical candidates show promise in targeting and treating cancers with unmet needs. Fusion has a strong financial position, with enough cash to fund operations until Q2 2025, and strategic partnerships to support its clinical pipeline.

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

HAMILTON, ON and BOSTON , Feb. 26, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences. TD Cowen 44th Annual Health Care Conference - The Company will participate in the "Prostate Cancer Corporate Panel Discussion" taking place on March 4, 2024, at 10:30 a.m.

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.